Your browser doesn't support javascript.
loading
Effect of vitamin A on recovery from the acute phase of multiple sclerosis-related optic neuritis, double-blind, randomized, placebo-controlled trial.
Rahimi-Dehgolan, Shiva; Masoudi, Maryam; Rahimi-Dehgolan, Shahram; Azimi, Amir Reza; Sahraian, Mohammad Ali; Baghbanian, Seyed Mohammad; Naser Moghadasi, Abdorreza.
Afiliação
  • Rahimi-Dehgolan S; Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical sciences, Tehran, Iran.
  • Masoudi M; Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical sciences, Tehran, Iran.
  • Rahimi-Dehgolan S; Physical Medicine and Rehabilitation Department, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
  • Azimi AR; Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical sciences, Tehran, Iran.
  • Sahraian MA; Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical sciences, Tehran, Iran.
  • Baghbanian SM; Department of Neurology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
  • Naser Moghadasi A; Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical sciences, Tehran, Iran.
Caspian J Intern Med ; 14(1): 23-30, 2023.
Article em En | MEDLINE | ID: mdl-36741486
ABSTRACT

Background:

Optic neuritis (ON) is one of the main neuro-ophthalmic presentations of multiple sclerosis (MS), and it causes optic nerve atrophy and axonal loss. However, so far, there is no effective treatment to improve long-term outcomes.

Methods:

In a double-blind placebo-controlled randomized clinical trial, 50 patients with MS-related ON were allocated into two arms (24 in the control group and 26 in the intervention group) receiving either 25000IU retinyl palmitate or an identical placebo for six months. Visual evoked potential (VEP), visual acuity, and the retinal nerve fiber layer (RNFL) thickness were evaluated and compared before and after the treatment.

Results:

RNFL thickness reduction in the affected eyes at sixth month compared to the baseline were 14.81 and 19.46 µm, in the intervention and control groups, respectively (P=0.017). However, VitA therapy did not affect visual acuity and VEP.

Conclusion:

Vitamin A supplementation in the patients with acute ON in MS could lessen optic nerve axonal loss.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Revista: Caspian J Intern Med Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Revista: Caspian J Intern Med Ano de publicação: 2023 Tipo de documento: Article